Compare CCC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | TNGX |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | 2185 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | N/A | 2020 |
| Metric | CCC | TNGX |
|---|---|---|
| Price | $4.46 | $28.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $8.94 | ★ $21.78 |
| AVG Volume (30 Days) | ★ 8.9M | 4.7M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $4.08 | $4.60 |
| 52 Week High | $8.68 | $34.39 |
| Indicator | CCC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 54.16 |
| Support Level | $4.08 | $19.74 |
| Resistance Level | $5.09 | N/A |
| Average True Range (ATR) | 0.25 | 2.56 |
| MACD | -0.02 | 0.58 |
| Stochastic Oscillator | 16.58 | 57.09 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.